191 related articles for article (PubMed ID: 29739434)
1. Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil.
Wang X; Liu Y; Diao Y; Gao N; Wan Y; Zhong J; Zheng H; Wang Z; Jin G
J Transl Med; 2018 May; 16(1):120. PubMed ID: 29739434
[TBL] [Abstract][Full Text] [Related]
2. Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects.
Wang XD; Gao NN; Diao YW; Liu Y; Gao D; Li W; Wan YY; Zhong JJ; Jin GY
World J Gastroenterol; 2015 Jul; 21(26):8052-60. PubMed ID: 26185376
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA
Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369
[TBL] [Abstract][Full Text] [Related]
4. [Combination of TLR7 agonist T7-ethacrynic acid conjugate with ROR1 has a stronger anti-breast cancer effect].
Zhang N; Jin G; Jin Z; Liu B; Peng B; Gao N; Hu Y; Tang L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Jul; 32(7):876-80. PubMed ID: 27363264
[TBL] [Abstract][Full Text] [Related]
5. A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma.
Lin G; Wang X; Yi W; Zhang C; Xu G; Zhu X; Cai Z; Liu Y; Diao Y; Lin MC; Jin G
J Transl Med; 2015 May; 13():166. PubMed ID: 25990580
[TBL] [Abstract][Full Text] [Related]
6. 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.
Correale P; Del Vecchio MT; Di Genova G; Savellini GG; La Placa M; Terrosi C; Vestri M; Urso R; Lemonnier F; Aquino A; Bonmassar E; Giorgi G; Francini G; Cusi MG
J Natl Cancer Inst; 2005 Oct; 97(19):1437-45. PubMed ID: 16204693
[TBL] [Abstract][Full Text] [Related]
7. Heat shock and HSP70 regulate 5-FU-mediated caspase-1 activation in myeloid-derived suppressor cells and tumor growth in mice.
Pilot T; Fratti A; Thinselin C; Perrichet A; Demontoux L; Limagne E; Derangère V; Ilie A; Ndiaye M; Jacquin E; Garrido C; Ghiringhelli F; Chalmin F; Rébé C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385145
[TBL] [Abstract][Full Text] [Related]
8. Mathematical modeling of tumor-induced immunosuppression by myeloid-derived suppressor cells: Implications for therapeutic targeting strategies.
Shariatpanahi SP; Shariatpanahi SP; Madjidzadeh K; Hassan M; Abedi-Valugerdi M
J Theor Biol; 2018 Apr; 442():1-10. PubMed ID: 29337259
[TBL] [Abstract][Full Text] [Related]
9. Conjugation of TLR7 Agonist Combined with Demethylation Treatment Improves Whole-Cell Tumor Vaccine Potency in Acute Myeloid Leukemia.
Zhong G; Jin G; Zeng W; Yu C; Li Y; Zhou J; Zhang L; Yu L
Int J Med Sci; 2020; 17(15):2346-2356. PubMed ID: 32922200
[No Abstract] [Full Text] [Related]
10. [Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].
Chi PD; Li L; Fan YY; Wu CY
Ai Zheng; 2007 Aug; 26(8):801-8. PubMed ID: 17697537
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of NLRP3 inflammasome activation in myeloid-derived suppressor cells by andrographolide sulfonate contributes to 5-FU sensitization in mice.
Xu L; Cai P; Li X; Wu X; Gao J; Liu W; Yang J; Xu Q; Guo W; Gu Y
Toxicol Appl Pharmacol; 2021 Oct; 428():115672. PubMed ID: 34391754
[TBL] [Abstract][Full Text] [Related]
12. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of low-dose fludarabine or 5-fluorouracil on the tumor growth and myeloid derived immunosuppression status of tumor-bearing mice.
Abedi-Valugerdi M; Zheng W; Benkessou F; Zhao Y; Hassan M
Int Immunopharmacol; 2017 Jun; 47():173-181. PubMed ID: 28411578
[TBL] [Abstract][Full Text] [Related]
14. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
[TBL] [Abstract][Full Text] [Related]
15. An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models.
Dharmapuri S; Aurisicchio L; Neuner P; Verdirame M; Ciliberto G; La Monica N
Cancer Gene Ther; 2009 May; 16(5):462-72. PubMed ID: 18989354
[TBL] [Abstract][Full Text] [Related]
16. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.
Triozzi PL; Aldrich W; Ponnazhagan S
Vaccine; 2010 Nov; 28(50):7837-43. PubMed ID: 20937315
[TBL] [Abstract][Full Text] [Related]
18. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
19. Modified Bu-zhong-yi-qi decoction synergies with 5 fluorouracile to inhibits gastric cancer progress via PD-1/PD- L1-dependent T cell immunization.
Xu R; Wu J; Zhang X; Zou X; Li C; Wang H; Yuan M; Chen M; Sun Q; Liu S
Pharmacol Res; 2020 Feb; 152():104623. PubMed ID: 31899315
[TBL] [Abstract][Full Text] [Related]
20. Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy.
Kim SY; Kim S; Kim JE; Lee SN; Shin IW; Shin HS; Jin SM; Noh YW; Kang YJ; Kim YS; Kang TH; Park YM; Lim YT
ACS Nano; 2019 Nov; 13(11):12671-12686. PubMed ID: 31589013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
